Have a feature idea you'd love to see implemented?
Let us know!
ADPT Adaptive Biotechnologies Corp
Price (delayed)
$4.64
Market cap
$684.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
$847.73M
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the
Highlights
ADPT's debt is down by 2.3% year-on-year
ADPT's equity is down by 39% year-on-year and by 12% since the previous quarter
The gross profit has declined by 24% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of ADPT
Market
Valuations
Earnings
Shares outstanding
147.47M
Market cap
$684.27M
Enterprise value
$847.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.83
Price to sales (P/S)
4.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.02
Revenue
$168.77M
EBIT
-$201.12M
EBITDA
-$173.75M
Free cash flow
-$136.59M
Per share
Balance sheet
Liquidity
EPS
-$1.47
Free cash flow per share
-$0.93
Book value per share
$1.64
Revenue per share
$1.14
TBVPS
$3.13
Total assets
$584.87M
Total liabilities
$343.44M
Debt
$226.26M
Equity
$241.6M
Working capital
$263.43M
Debt to equity
0.94
Current ratio
3.99
Quick ratio
3.75
Net debt/EBITDA
-0.94
Margins
Efficiency
Dividend
EBITDA margin
-103%
Gross margin
54.8%
Net margin
-126.5%
Operating margin
-129.2%
Return on assets
-33%
Return on equity
-72%
Return on invested capital
-34.2%
Return on capital employed
-40.5%
Return on sales
-119.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADPT stock price
How has the Adaptive Biotechnologies stock price performed over time
Intraday
-3.33%
1 week
-5.5%
1 month
0.22%
1 year
4.5%
YTD
-5.31%
QTD
-9.38%
Financial performance
How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$168.77M
Gross profit
$92.44M
Operating income
-$218.1M
Net income
-$213.47M
Gross margin
54.8%
Net margin
-126.5%
Adaptive Biotechnologies's operating margin has decreased by 29% YoY and by 3.1% QoQ
ADPT's net margin is down by 26% year-on-year and by 2.7% since the previous quarter
The gross profit has declined by 24% year-on-year and by 7% since the previous quarter
Adaptive Biotechnologies's operating income has decreased by 15% YoY
Growth
What is Adaptive Biotechnologies's growth rate over time
Valuation
What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
2.83
P/S
4.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.02
ADPT's EPS is down by 11% year-on-year
ADPT's P/B is 45% below its 5-year quarterly average of 5.1 but 35% above its last 4 quarters average of 2.1
ADPT's equity is down by 39% year-on-year and by 12% since the previous quarter
ADPT's price to sales (P/S) is 84% lower than its 5-year quarterly average of 25.6 but 13% higher than its last 4 quarters average of 3.6
The revenue has contracted by 11% YoY and by 3.3% from the previous quarter
Efficiency
How efficient is Adaptive Biotechnologies business performance
The ROE has shrunk by 67% YoY and by 12% QoQ
Adaptive Biotechnologies's ROA has decreased by 42% YoY and by 6% from the previous quarter
The ROIC has contracted by 34% YoY and by 5% from the previous quarter
ADPT's return on sales is down by 26% year-on-year and by 3.1% since the previous quarter
Dividends
What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADPT.
Financial health
How did Adaptive Biotechnologies financials performed over time
The total assets is 70% more than the total liabilities
The total assets has contracted by 24% YoY and by 6% from the previous quarter
The quick ratio has declined by 21% year-on-year and by 12% since the previous quarter
ADPT's debt is 6% smaller than its equity
ADPT's debt to equity has surged by 59% year-on-year and by 13% since the previous quarter
ADPT's equity is down by 39% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.